Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

▤ Summary

Shattuck Labs will host an investor call and webcast on June 8, 2026 to share Phase 1 clinical data for SL-325 and give a pipeline update. The company says the readout will cover safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity. Management will present the results and then take questions from investors. Shattuck Labs describes SL-325 as a potentially first-in-class DR3-blocking antibody in development for inflammatory and immune-mediated diseases.

▦ Linked Companies